Benralizumab strongly reduces blood basophils in severe eosinophilic asthma
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:50 |
|---|---|
| Enthalten in: |
Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology - 50(2020), 11 vom: 19. Nov., Seite 1267-1269 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Lommatzsch, Marek [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
71492GE1FX |
|---|
| Anmerkungen: |
Date Completed 02.11.2021 Date Revised 02.11.2021 published: Print-Electronic ClinicalTrials.gov: NCT03652376 Citation Status MEDLINE |
|---|
| doi: |
10.1111/cea.13720 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM313371377 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM313371377 | ||
| 003 | DE-627 | ||
| 005 | 20231225150430.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/cea.13720 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1044.xml |
| 035 | |a (DE-627)NLM313371377 | ||
| 035 | |a (NLM)32762056 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Lommatzsch, Marek |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Benralizumab strongly reduces blood basophils in severe eosinophilic asthma |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 02.11.2021 | ||
| 500 | |a Date Revised 02.11.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a ClinicalTrials.gov: NCT03652376 | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Clinical Study | |
| 650 | 4 | |a Letter | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Anti-Asthmatic Agents |2 NLM | |
| 650 | 7 | |a Antibodies, Monoclonal, Humanized |2 NLM | |
| 650 | 7 | |a benralizumab |2 NLM | |
| 650 | 7 | |a 71492GE1FX |2 NLM | |
| 700 | 1 | |a Marchewski, Hannes |e verfasserin |4 aut | |
| 700 | 1 | |a Schwefel, Georg |e verfasserin |4 aut | |
| 700 | 1 | |a Stoll, Paul |e verfasserin |4 aut | |
| 700 | 1 | |a Virchow, Johann Christian |e verfasserin |4 aut | |
| 700 | 1 | |a Bratke, Kai |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology |d 1990 |g 50(2020), 11 vom: 19. Nov., Seite 1267-1269 |w (DE-627)NLM012617121 |x 1365-2222 |7 nnns |
| 773 | 1 | 8 | |g volume:50 |g year:2020 |g number:11 |g day:19 |g month:11 |g pages:1267-1269 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/cea.13720 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 50 |j 2020 |e 11 |b 19 |c 11 |h 1267-1269 | ||